Rabeprazole

Sample preparation Mix 1 mL plasma with 100 ixL 1% diethylamine in water, add 100 aL 0.1% diethylamine in MeOH, add 1 mL pH 10.38 Britton-Robinson buffer, add 4 mL ethyl acetate, shake for 10 min, centrifiige at 1500 g for 5 min, repeat extraction twice. Combine the organic layers and evaporate to dryness under a stream of nitrogen at 40°, reconstitute the residue with 100 iL 0.1% diethylamine in MeOH, inject a 30 ixL aliquot. 

Mobile phase MeCNrlOO mM pH 7.00 phosphate buffer 28 72, adjusted to pH 7.00 with phosphoric acid 

Internal standard IS735 (5-methyl-2-[ 4-(3-methoxypropoxy)-3-methylp3rridin-2-yl methylsulfinyl]-lH-benzimidazole sodium salt) (10.1) 

Shimamura, Y. Kanazawa, T. Yasuda, S. Kayano, M. Determination of a new H+-K+ ATPase inhibitor (E3810) and its four metabolites in human plasma by high-performance liquid chromatography, J.Chromatogr.B, 1994, 660, 211-220. 

Sample preparation Weigh out powdered tablet containing 15 mg rabeprazole, dissolve in 100 mL water, filter, inject a 20 xL aliquot. 

---

The proton pump inhibitors are contraindicated in patients who have hypersensitivity to any of the drags. Omeprazole (Pregnancy Category C) and lansoprazole, rabeprazole, and pantoprazole (Pregnancy Category B) are contraindicated during pregnancy and lactation. The proton pump inhibitors are used cautiously in older adults and in patients with hepatic impairment. 

C13H19NO4 117977-19-2) see Rabeprazole sodium 3P-acetoxy-16-methyl-20-oxo-5,16-pregnadiene... 

Omeprazole 20-40 mg enterally daily ° Esomeprazole 20-40 mg enterally daily or ql2h ° Lansoprazole 30 mg enterally or IV daily ° Pantoprazole 40 mg enterally or IV daily or 12h ° Rabeprazole 20 mg enterally daily... 

H2 receptor antagonists (Cimetidine, famotidine, nizatidine, ranitidine) Proton pump inhibitors Lansoprazole Omeprazole Pantoprazole Rabeprazole... 

PPIs (taken once daily) for 4-8 weeks - Esomeprazole 20 mg - Lansoprazole 1 5-30 mg - Omeprazole 20 mg - Pantoprazole 40 mg - Rabeprazole 20 mg therapy. 

Rabeprazole 20 mg Palienls not responding to acid-suppressing therapy,... 

Comparable daily doses of PPIs are omeprazole 20 mg = esomeprazole 20 mg = lansoprazole 30 mg = rabeprazole 20 mg = pantoprazole 40 mg. The PPIs degrade in acidic environments and are therefore formulated in delayed-release capsules or tablets.16 Lansoprazole, esomeprazole, and omeprazole contain enteric-coated (pH-sensitive) granules in a capsule form. For patients unable to swallow the capsule or in pediatric patients, the contents of the capsule can be mixed in applesauce or placed in orange juice. If a patient has a nasogastric tube, the contents of an omeprazole capsule can be... 

Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related disorders. J Am Pharm Assoc 2000 40 52-62. 

The histamine2-receptor antagonists or H2RAs (cimetidine, famotidine, nizatidine, and ranitidine) and proton pump inhibitors (omeprazole, esomeprazole, lansoprazole, pantopra-zole, and rabeprazole) reduce the amount of acid secreted into the stomach by gastric parietal cells. These agents are also helpful for nausea and vomiting related to gastric acid secretion. 

Esomeprazole (Nexium) Lansoprazole (Prevacid) Omeprazole (Prilosec) Panloprazole (Protonix) Rabeprazole (Aciphex)... 

Wong WM, Gu Q, Lam SK, Fung FM, Lai KC, Hu WH, Yee YK, Chan CK, Xia HH, Yuen MF, Wong BC Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment Pharmacol Ther 2003 17 553-560. 

Most patients require standard doses to prevent relapses. H2RAs may be an effective maintenance therapy in patients with mild disease. The PPIs are the drugs of choice for maintenance treatment of moderate to severe esophagitis. Usual once-daily doses are omeprazole 20 mg, lansoprazole 30 mg, rabeprazole 20 mg, or esomeprazole 20 mg. Lower doses of a PPI or alternate-day regimens may be effective in some patients with less severe disease. 

---